Graphene-Based Sensor Helps Predict Asthma Attacks
By LabMedica International staff writers Posted on 05 Jun 2017 |

Image: Exhaled breath condensate is rapidly analyzed by a new graphene-based nanoelectronic sensor that detects nitrite, a key inflammatory marker in the inner lining of the respiratory airway (Photo courtesy of Azam Gholizadeh, Rutgers University).
Researchers have developed a prototype graphene-based device that detects inflammation in lungs, which could lead to earlier detection of asthma attacks and improve the management of asthma and other respiratory diseases, preventing hospitalizations and deaths. The invention helps pave the way for developing small wearable devices that could indicate when and at what dosage to take medication.
A diverse team of experts at Rutgers University-New Brunswick (New Brunswick, NJ, USA) created the sensor in response to the need for improved, minimally invasive methods for the molecular diagnosis and monitoring of asthma. Today’s non-invasive methods are limited in characterizing the nature and degree of airway inflammation, and require costly, bulky equipment that patients cannot easily keep with them. The methods include spirometry, which measures breathing capacity, and testing for exhaled nitric oxide, an indicator of airway inflammation.
Asthma causes inflammation of the airway and obstructs airflow. Other serious lung ailments include chronic obstructive pulmonary disease (COPD), which encompasses emphysema and chronic bronchitis.
“Our vision is to develop a device that someone with asthma or another respiratory disease can wear around their neck or on their wrist and blow into it periodically to predict the onset of an asthma attack or other problems,” said Mehdi Javanmard, assistant professor at Rutgers, “It advances the field of personalized and precision medicine.” Measuring biomarkers in exhaled breath condensate (tiny liquid droplets discharged during breathing) can also contribute to understanding asthma at the molecular level and lead to targeted treatment and better disease management.
Graphene is a thin layer of the graphite used in pencils. The new miniaturized electrochemical sensor accurately measures nitrite in exhaled breath condensate using reduced graphene oxide, which resists corrosion, has superior electrical properties, and is very accurate in detecting biomarkers.
“Nitrite level in breath condensate is a promising biomarker for inflammation in the respiratory tract. Having a rapid, easy method to measure it can help an asthmatic determine if air pollutants are affecting them so they can better manage use of medication and physical activity,” said Clifford Weisel, study co-author and professor at Rutgers, “It could also be used in a physician’s office and emergency departments to monitor the effectiveness of various anti-inflammatory drugs to optimize treatment.”
“Increases in airway inflammation may be an early warning sign of increased risk of an asthma attack or exacerbation of COPD, allowing for earlier and more-effective preventive measures or treatment,” said Robert Laumbach, study co-author and an occupational and environmental medicine physician at Rutgers.
“Just looking at coughing, wheezing, and other outward symptoms, diagnosis accuracy is often poor,” said Prof. Javanmard, “The ability to perform label-free quantification of nitrite content in exhaled breath condensate in a single step without any sample pre-treatment resolves a key bottleneck to enabling portable asthma management.” The next step is to develop a portable, wearable system. The researchers also envision expanding the number of inflammation biomarkers a device could detect and measure.
The study, by Gholizadeh A et al, was published May 22, 2017, in the journal Microsystems & Nanoengineering.
Related Links
Rutgers University-New Brunswick
A diverse team of experts at Rutgers University-New Brunswick (New Brunswick, NJ, USA) created the sensor in response to the need for improved, minimally invasive methods for the molecular diagnosis and monitoring of asthma. Today’s non-invasive methods are limited in characterizing the nature and degree of airway inflammation, and require costly, bulky equipment that patients cannot easily keep with them. The methods include spirometry, which measures breathing capacity, and testing for exhaled nitric oxide, an indicator of airway inflammation.
Asthma causes inflammation of the airway and obstructs airflow. Other serious lung ailments include chronic obstructive pulmonary disease (COPD), which encompasses emphysema and chronic bronchitis.
“Our vision is to develop a device that someone with asthma or another respiratory disease can wear around their neck or on their wrist and blow into it periodically to predict the onset of an asthma attack or other problems,” said Mehdi Javanmard, assistant professor at Rutgers, “It advances the field of personalized and precision medicine.” Measuring biomarkers in exhaled breath condensate (tiny liquid droplets discharged during breathing) can also contribute to understanding asthma at the molecular level and lead to targeted treatment and better disease management.
Graphene is a thin layer of the graphite used in pencils. The new miniaturized electrochemical sensor accurately measures nitrite in exhaled breath condensate using reduced graphene oxide, which resists corrosion, has superior electrical properties, and is very accurate in detecting biomarkers.
“Nitrite level in breath condensate is a promising biomarker for inflammation in the respiratory tract. Having a rapid, easy method to measure it can help an asthmatic determine if air pollutants are affecting them so they can better manage use of medication and physical activity,” said Clifford Weisel, study co-author and professor at Rutgers, “It could also be used in a physician’s office and emergency departments to monitor the effectiveness of various anti-inflammatory drugs to optimize treatment.”
“Increases in airway inflammation may be an early warning sign of increased risk of an asthma attack or exacerbation of COPD, allowing for earlier and more-effective preventive measures or treatment,” said Robert Laumbach, study co-author and an occupational and environmental medicine physician at Rutgers.
“Just looking at coughing, wheezing, and other outward symptoms, diagnosis accuracy is often poor,” said Prof. Javanmard, “The ability to perform label-free quantification of nitrite content in exhaled breath condensate in a single step without any sample pre-treatment resolves a key bottleneck to enabling portable asthma management.” The next step is to develop a portable, wearable system. The researchers also envision expanding the number of inflammation biomarkers a device could detect and measure.
The study, by Gholizadeh A et al, was published May 22, 2017, in the journal Microsystems & Nanoengineering.
Related Links
Rutgers University-New Brunswick
Latest Immunology News
- Blood Test Detects Organ Rejection in Heart Transplant Patients
- Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
- Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
- New Tool Detects Breast Cancer Relapses Five Years in Advance
- T Cells in Blood Can Detect Parkinson's Years Before Diagnosis
- POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood
- Treatment Switching Guided by Liquid Biopsy Blood Tests Improves Outcomes for Breast Cancer Patients
- First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop
- Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
- Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
- Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
- Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
- New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
- Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
- Novel Analytical Method Tracks Progression of Autoimmune Diseases
Channels
Clinical Chemistry
view channel
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreMolecular Diagnostics
view channel
RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia
A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more
New Technique for Measuring Acidic Glycan in Blood Simplifies Schizophrenia Diagnosis
Polysialic acid is a unique acidic glycan predominantly found in brain regions associated with memory and emotion, but it is also present in the bloodstream. Research has shown that blood levels of polysialic... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
Blood Test Detects Organ Rejection in Heart Transplant Patients
Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read moreMicrobiology
view channel
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read morePathology
view channel
AI Performs Virtual Tissue Staining at Super-Resolution
Conventional histopathology, essential for diagnosing various diseases, typically involves chemically staining tissue samples to reveal cellular structures under a microscope. This process, known as “histochemical... Read more
AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis
Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response
Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy
Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read moreIndustry
view channel
Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
Lunit (Seoul, South Korea) and Microsoft (Redmond, WA, USA) have entered into a collaboration to accelerate the delivery of artificial intelligence (AI)-powered healthcare solutions. In conjunction with... Read more